Canada Markets closed

Merck & Co., Inc. (MRK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
93.55+1.46 (+1.59%)
At close: 04:03PM EDT
93.82 +0.27 (+0.29%)
After hours: 07:59PM EDT
Sign in to post a message.
  • S
    Sigrid V
    Maybe Merck will have stock split. Google and Amazon are expected to split soon. I'd love it if Merck had a split.
  • C
    Cured
    $SLS conversation
    $MRK Gps Keytruda Ovarian Cancer last update "Median overall survival among the patients in this trial is not yet known as all patients are still alive at the time of the analysis, which period of time exceeds nine months.
    Avg Os with existing soc is 9/10 months
    “Based on these early data, it is encouraging to see the induction of WT1-specific T-cell immune responses with the administration of GPS in combination with pembrolizumab with a validated complex ex-vivo immune response assay on peripheral blood from patients with platinum-refractory metastatic ovarian cancer who had undergone numerous prior therapies,” Jeffrey S. Weber, MD, PhD, the deputy director of the Perlmutter Cancer Center at NYU Langone Health, and chair of SELLAS’ Scientific Advisory Board, added in the press release.
  • B
    Berlin 68
    $SLS conversation
    Possible reasons for trading activity
    $ABBV buys SLS, $MRK Buys SLS, $BMY BUYS SLS, IDMC Halts the Phase 3 for Efficacy, FDA AML Approval
  • R
    Ryan
    Putting our time and effort in activities and investment that will yield a profitable returns in the futures is what we should be aiming for.
  • B
    Brent
    MRK trading at 12x this year's earnings is far from being expensive. Over $100 soon.
  • T
    The REAL Chewdog
    Somethings up besides the sp. opened down on 1.2 M shares now up much more at 2.3 M—-we usually don’t get this much attention
  • C
    Cured
    $SLS conversation
    Last june SlS traded up to $15 ahead of small adhoc readouts. Now we will see larger, mature results - Gps is worth billions and Big Pharma will be Paying up Bigly. $MRK or $BMY May decide its time to Guppy this baby BIO
    Merck has zero agents for PROC, Keytruda is ineffective as a single agent - they need Gps.
  • A
    Alexander
    Reading about people grabbing multi-figures monthly as incomes in crypto investments even in this crazy days in the market, any way or any pointers on how to make substantial progress in earning ? would appreciate
  • S
    Sumerian
    Merck benefited from that failure of the phase 3 trial for Roche’s immune checkpoint inhibitor tiragolumab failed in non-small cell lung cancer, both on the co-primary endpoint of progression-free survival (PFS).
  • R
    Real Immuno Investor 10
    $SLS conversation
    SLS is worth a Billion Now trades for $50M $bmy $mrk In June Gps Keytruda Ovarian Cancer last update "Median overall survival among the patients in this trial is not yet known as all patients are still alive at the time of the analysis, which period of time exceeds nine months.
    Gps Opdivo End stage Meso last update:
    “Median OS was 35.4 weeks, the time at which the data was taken. Stergiou expects the median overall survival to be considerably longer when the next report is delivered
    ..patients with relapsed or refractory mesothelioma have a median OS of 22
  • J
    Joe
    $SLS conversation
    Last year, this time SlS traded up to $15 ahead of small adhoc readouts. Now we will see larger, mature results - Gps is worth billions and Big Pharma will be Paying up Bigly. $MRK or $BMY May decide its time to Guppy this baby BIO
    Merck has zero agents for PROC, Keytruda is ineffective as a single agent - they need Gps.
  • C
    Clifford
    New all time high
  • A
    Always
    I love MRK
  • J
    Joe
    Boom! 💥
  • R
    Real Immuno Investor 10
    $SLS conversation
    PT $40 $50 "...by the End of Q2" SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely
  • A
    A
    Not gonna lie but after the last three weeks I'm about ready to give my MRK shares a hug...
  • R
    Real Immuno Investor 10
    $SLS conversation
    PT $40 $50 "...by the End of Q2" SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely
  • R
    Real Immuno Investor 10
    $SLS conversation
    PT $40 $50 "...by the End of Q2" SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely

    20M shares x $40 $800M Mc for an effective safe therapy that works for end stage, dying mesothelioma and ovarian cancer patients who have exhausted all treatment options.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Last year, this time SlS traded up to $15 ahead of small adhoc readouts. Now we will see larger, mature results - Gps is worth billions and Big Pharma will be Paying up Bigly. $MRK or $BMY May decide its time to Guppy this baby BIO
    Merck has zero agents for PROC, Keytruda is ineffective as a single agent - they need Gps.
  • j
    joeri
    ATH!